Hikma Pharmaceuticals Plc Holding(s) in Company (7337F)
May 28 2013 - 12:24PM
UK Regulatory
TIDMHIK
RNS Number : 7337F
Hikma Pharmaceuticals Plc
28 May 2013
Notification of major interests in shares
LONDON, 28 May 2013 - Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals
group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
----------------------------------------- --------------------------
2 Reason for the notification
--------------------------------------------------------- ----
An acquisition or disposal of voting rights Yes
--------------------------------------------------------- ----
An acquisition or disposal of financial instruments No
which may result in the acquisition of shares already
issues to which voting rights are attached
--------------------------------------------------------- ----
An event changing the breakdown of voting rights No
--------------------------------------------------------- ----
Other (please specify): Compliance with the Transparency No
Directive
--------------------------------------------------------- ----
3 Full name of the person subject to the FMR LLC
notification obligation
----- --------------------------------------------------------------- --------------------------------------
4 Full name of shareholders See attached schedule
----- --------------------------------------------------------------- --------------------------------------
5 Date of the Transaction (and date on 24 May 2013
which the threshold crossed is reached
differently)
----- --------------------------------------------------------------- --------------------------------------
6 Date on which the issuer notified 28 May 2013
----- --------------------------------------------------------------- --------------------------------------
7 Threshold that is crossed 5%
----- --------------------------------------------------------------- --------------------------------------
8 Notified details See A, B & C below
----- --------------------------------------------------------------- --------------------------------------
A. Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------ ------------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----- --------- ----------- ----------- ------------------- --------------------- ----------------------
Direct Indirect Direct Indirect Direct Indirect
----- --------- ----------- ----------- ------- ---------- --------- ---------- ------- -------------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 9,981,498 9,981,498 0 9,873,932 0 9,873,932 4.99 9,981,498
---------------- ----------- ----------- ------- ---------- --------- ---------- ------- -------------
B. Qualifying Financial instruments
----------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
------------------ ----------- -------------------- ------------------------ -------------------
- - - - -
------------------ ----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
------------ --------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
------------ --------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
------------ --------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
9,873,932 4.99%
------------------------ -------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
----------------------------------------------------------------------
Proxy Voting
--------------------------------------------------------------------------------------------------------------------
10 Name of the proxy holder Custodian Advisor Total
BANK OF NEW YORK PGATC-PYRAMIS GLOBAL ADVISORS
MELLON TRUST COMPANY 444,863
BROWN BROTHERS HARRIMAN PGALLC-PYRAMIS GLOBAL ADVISORS,
AND CO LLC. 77,902
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 1,470,792
CIBC MELLON TRUST PGALLC-PYRAMIS GLOBAL ADVISORS,
(C) LLC. 21,864
JPMORGAN CHASE BANK FMR-FIDELITY MANAGEMENT AND RESEARCH 2,895,828
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC. 303,907
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 41,532
PGALLC-PYRAMIS GLOBAL ADVISORS,
MELLON BANK NA (C) LLC. 458,294
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 519,332
NATIONAL BANK TRUST FIDELITY INVTS-FIDELITY INVESTMENTS
(C) CANADA 22,024
NORTHERN TRUST CO
(C) FMR-FIDELITY MANAGEMENT AND RESEARCH 1,964,745
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 309,862
RBC INVESTOR SERV PGA UK LTD-PYRAMIS GLOBAL ADVISORS
ZURICH (C) UK LTD 73,004
ROYAL TRUST- TORONTO FIDELITY INVTS-FIDELITY INVESTMENTS
(C) CANADA 59,478
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC. 17,862
STATE STREET BANK
AND TR CO FMR-FIDELITY MANAGEMENT AND RESEARCH 213,380
PGALLC-PYRAMIS GLOBAL ADVISORS,
LLC. 491,336
PGATC-PYRAMIS GLOBAL ADVISORS
TRUST COMPANY 432,657
SAI-STRATEGIC ADVISERS GROUP 30,113
PGALLC-PYRAMIS GLOBAL ADVISORS,
US BANK NA (C) LLC. 25,157
Grand Total 9,873,932
----------------------------------------------------------------- ----------
--- ------------------------------ -------------------------------------------------------------------------------
11 Number of voting rights proxy N/A
holder will cease to hold
--- ------------------------------ -------------------------------------------------------------------------------
12 Date on which proxy holder N/A
will cease to hold voting
rights
--- ------------------------------ -------------------------------------------------------------------------------
13 Additional Information
--- -------------------------- --------------------------------
14 Contact name: Peter Speirs, Company Secretary
--- -------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
--- -------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUWUNROUAVUAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
